
|Articles|February 9, 2015
Testosterone Therapy and Cardiovascular Risk
Advertisement
Dr. Abraham Morgentaler, an Associate Clinical Professor of Urology at Harvard Medical School and affiliated with Beth Israel Deaconess Medical Center, in Boston, MA, along with his coauthors, explore and clarify in the February 2015 issue of Mayo Clinic Proceedings, the value of testosterone therapy in men, and in particular the issue of cardiovascular risk.
Source:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











